--- title: "Palatin Technologies (PTN) news: delisting and going concern" url: "https://aibio.space/companies/palatin-technologies/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "PTN delisting and going concern news: Palatin Technologies gets NYSE American delisting notice, plans to appeal. Palatin Technologies, Inc." --- PTN Palatin Technologies, Inc. NASDAQ · United States # Palatin Technologies (PTN) news PTN delisting and going concern news Listings · 2026-05-18 ## [Palatin Technologies to move stock listing from NYSE American to Nasdaq Capital Market](https://aibio.space/news/palatin-technologies-move-stock-listing-nyse-american-nasdaq-capital/) Palatin will switch from NYSE American to the Nasdaq Capital Market, with its last NYSE American trading day on May 28, 2026. The move needs no shareholder action, but the company's annual report carries a going-concern warning. ## Latest Palatin Technologies news 1. 2025-04-10 Listings [Palatin Technologies gets NYSE American delisting notice, plans to appeal](https://aibio.space/news/palatin-technologies-gets-nyse-american-delisting-notice-plans-appeal/) NYSE Regulation said it will start proceedings to delist Palatin Technologies (NYSE American: PTN) after the company did not regain compliance within an 18-month plan period. Palatin intends to appeal. ## Palatin Technologies at a glance - **Ticker**: PTN - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $7.5 million ### Related companies - [Harmony Biosciences Holdings](https://aibio.space/companies/harmony-biosciences/) NASDAQ: HRMY - [Kairos Pharma](https://aibio.space/companies/kairos-pharma/) AMEX: KAPA - [Madrigal Pharmaceuticals](https://aibio.space/companies/madrigal-pharmaceuticals/) NASDAQ: MDGL - [Keros Therapeutics](https://aibio.space/companies/keros-therapeutics/) NASDAQ: KROS - [Tempest Therapeutics](https://aibio.space/companies/tempest-therapeutics/) NASDAQ: TPST - [Retrieve Medical Holdings](https://aibio.space/companies/retrieve-medical/) OTC: RMHI - [Protara Therapeutics](https://aibio.space/companies/protara-therapeutics/) NASDAQ: TARA - [Indivior Pharmaceuticals](https://aibio.space/companies/indivior-pharmaceuticals/) NASDAQ: INDV ### Also on NASDAQ - [Filana Therapeutics](https://aibio.space/companies/filana-therapeutics/) FLNA - [Corcept Therapeutics](https://aibio.space/companies/corcept-therapeutics/) CORT - [Cullinan Therapeutics](https://aibio.space/companies/cullinan-therapeutics/) CGEM - [Niagen Bioscience](https://aibio.space/companies/niagen-bioscience/) NAGE - [Microbot Medical](https://aibio.space/companies/microbot-medical/) MBOT - [Anavex Life Sciences](https://aibio.space/companies/anavex-life-sciences/) AVXL ## What Palatin Technologies does Palatin Technologies, Inc. is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the melanocortin receptor system. Its product candidates are targeted, receptor-specific therapeutics for diseases with significant unmet medical need. Its development activities focus mainly on MC4R agonists for obesity, including a modified MC4R peptide with an extended drug half-life and an MC4R selective oral small molecule, with potential use in rare MC4R pathway diseases such as hypothalamic obesity. It is also developing MC1R agonist peptides for inflammatory and autoimmune diseases, such as dry eye disease, uveitis, diabetic retinopathy and inflammatory bowel disease. Its FDA-approved melanocortin receptor agonist, Vyleesi, is an as-needed therapy for premenopausal women with hypoactive sexual desire disorder and was acquired by Cosette in December 2023. The company retains rights to PL9643, which completed an initial Phase 3 trial for dry eye disease and was licensed to Altanispac Labs, LLC in January 2026. | Product or program | What it is | Stage | |---|---|---| | MC4R selective agonist peptides and small molecules | Long-acting peptide and oral small molecule agonists for obesity and rare MC4R pathway diseases | in development | | Vyleesi | As-needed treatment for hypoactive sexual desire disorder in premenopausal women | approved by the FDA | | PL9643 | Melanocortin receptor agonist for dry eye disease | initial Phase 3 trial completed; licensed to Altanispac Labs, LLC | | MC1R agonist peptides | Anti-inflammatory peptides for ocular, gut and kidney indications | in development, dependent on resources | Summarised from the company's [10-K filed Sep 28, 2026](https://www.sec.gov/Archives/edgar/data/911216/000149315226044572/form10-k.htm). ## Palatin Technologies annual financials | Line | FY ended Jun 30, 2026 | FY ended Jun 30, 2025 | |---|---|---| | Revenue | [$8.8 million](https://www.sec.gov/Archives/edgar/data/911216/000149315226044572/) | [$0](https://www.sec.gov/Archives/edgar/data/911216/000165495425011030/) | | Research and development | [$12.4 million](https://www.sec.gov/Archives/edgar/data/911216/000149315226044572/) | [$14.9 million](https://www.sec.gov/Archives/edgar/data/911216/000149315226044572/) | | Net income (loss) | [-$8.4 million](https://www.sec.gov/Archives/edgar/data/911216/000149315226044572/) | [-$17.3 million](https://www.sec.gov/Archives/edgar/data/911216/000149315226044572/) | | Cash from operations | [-$13.5 million](https://www.sec.gov/Archives/edgar/data/911216/000149315226044572/) | [-$21.3 million](https://www.sec.gov/Archives/edgar/data/911216/000149315226044572/) | | Cash and equivalents | [$7.5 million](https://www.sec.gov/Archives/edgar/data/911216/000149315226044572/) | [$2.6 million](https://www.sec.gov/Archives/edgar/data/911216/000149315226044572/) | Latest balance sheet, Jun 30, 2026 (10-K): cash and equivalents $7.5 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Palatin Technologies Was Palatin Technologies delisted? Our latest story on this, dated Apr 10, 2025: "Palatin Technologies gets NYSE American delisting notice, plans to appeal". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/palatin-technologies-gets-nyse-american-delisting-notice-plans-appeal/). Has Palatin Technologies issued a going-concern warning? Our latest story on this, dated May 18, 2026: "Palatin Technologies to move stock listing from NYSE American to Nasdaq Capital Market". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/palatin-technologies-move-stock-listing-nyse-american-nasdaq-capital/). What is the ticker symbol of Palatin Technologies? Palatin Technologies, Inc. trades under the ticker PTN on NASDAQ. Where is Palatin Technologies listed? Palatin Technologies, Inc. is listed on NASDAQ. Our directory also records these other listings: LSE:0KF3. What is the SEC CIK of Palatin Technologies? The SEC Central Index Key (CIK) for Palatin Technologies, Inc. is 911216. Its filings are on SEC EDGAR. How many shares does Palatin Technologies have outstanding? 1,780,939 shares as of 2026-09-25, per the cover page of its 10-K filed 2026-09-28. Which country or territory is Palatin Technologies listed under? Our directory records Palatin Technologies, Inc. under United States. What does Palatin Technologies do? Our directory classifies Palatin Technologies, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Palatin Technologies? The ISIN recorded for Palatin Technologies, Inc. is US6960776010. Does aibio.space cover Palatin Technologies? aibio.space lists Palatin Technologies, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Palatin Technologies incorporated? SEC records list its state or country of incorporation as NJ. What does Palatin Technologies develop? Palatin Technologies, Inc. is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the melanocortin receptor system. Its product candidates are targeted, receptor-specific therapeutics for diseases with significant unmet medical need. What is MC4R selective agonist peptides and small molecules from Palatin Technologies? MC4R selective agonist peptides and small molecules: Long-acting peptide and oral small molecule agonists for obesity and rare MC4R pathway diseases Stage: in development. What is Vyleesi from Palatin Technologies? Vyleesi: As-needed treatment for hypoactive sexual desire disorder in premenopausal women Stage: approved by the FDA. What was Palatin Technologies's revenue last year? $8.8 million for the fiscal year ended Jun 30, 2026, as reported to the SEC. ## Investor discussion: Palatin Technologies Members talk about Palatin Technologies (PTN). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Palatin Technologies, newest first. Each line links the filing it comes from. 1. 2026-09-28 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/911216/000149315226044572/form10-k.htm) 2. 2026-05-28 Listings Filed to remove its shares from exchange listing. SEC Form 25. [Source](https://www.sec.gov/Archives/edgar/data/911216/000149315226025603/form25.htm) 3. 2026-05-18 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/911216/000149315226024219/ex99-1.htm) 4. 2025-11-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/911216/000165495425012928/ptn_ex991.htm) 5. 2025-11-06 Financings Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/911216/000165495425012641/ptn_ex991.htm) 6. 2025-10-01 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/911216/000165495425011273/ptn_s1.htm) 7. 2025-09-22 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/911216/000165495425010973/ptn_ex991.htm) 8. 2025-09-10 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/911216/000165495425010576/ptn_8k.htm) 9. 2025-08-18 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/911216/000165495425009743/ptn_ex991.htm) 10. 2025-08-08 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/911216/000165495425009290/ptn_ex991.htm) 11. 2025-07-29 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/911216/000165495425008579/ptn_8k.htm) 12. 2025-07-09 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/911216/000165495425007872/ptn_8k.htm) 13. 2025-06-30 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/911216/000165495425007537/ptn_def14a.htm) 14. 2025-06-18 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/911216/000165495425007152/ptn_pre14a.htm) 15. 2025-05-08 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,3.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/911216/000165495425005296/ptn_ex991.htm) 16. 2025-04-10 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/911216/000165495425004125/ptn_ex991.htm) 17. 2025-03-31 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/911216/000165495425003691/ptn_s1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:PTN on TradingView](https://www.tradingview.com/symbols/NASDAQ-PTN/). ## SEC filings and registration - **SEC name**: Palatin Technologies Inc - **CIK**: 911216 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: PTN (Nasdaq) - **State or country of incorporation**: NJ - **Fiscal year ends**: June 30 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 4B CEDAR BROOK DRIVE, CRANBURY, NJ, 08512 - **Phone**: 609-495-2200 - **Shares outstanding**: 1,780,939 as of 2026-09-25 (10-K filed 2026-09-28) - **Former names**: INTERFILM INC ### Recent filings (8-K and 6-K are the company's own announcements) - [10-K](https://www.sec.gov/Archives/edgar/data/911216/000149315226044572/form10-k.htm) filed 2026-09-28 - [8-K](https://www.sec.gov/Archives/edgar/data/911216/000149315226035722/form8-k.htm) filed 2026-08-03 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/911216/000149315226030126/formdef14a.htm) filed 2026-06-25 - [8-K](https://www.sec.gov/Archives/edgar/data/911216/000149315226024219/form8-k.htm) filed 2026-05-18 - [10-Q](https://www.sec.gov/Archives/edgar/data/911216/000149315226022778/form10-q.htm) filed 2026-05-13 - [10-Q](https://www.sec.gov/Archives/edgar/data/911216/000149315226006969/form10-q.htm) filed 2026-02-17 - [10-Q](https://www.sec.gov/Archives/edgar/data/911216/000165495425013091/ptn_10q.htm) filed 2025-11-14 - [8-K](https://www.sec.gov/Archives/edgar/data/911216/000165495425012928/ptn_8k.htm) filed 2025-11-12 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000911216), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Palatin Technologies, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PTN, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Palatin Technologies, Inc. - **Ticker**: PTN - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US6960776010 - **Other listed symbols**: LSE:0KF3 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-PTN/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/palatin-technologies/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Palatin Technologies (PTN) news: delisting and going concern", 2026-10-31, https://aibio.space/companies/palatin-technologies/